Ken Griffin Champions Oncology, Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.5 - $5.23 $11,731 - $13,634	-2,607 Reduced 20.33%	10,218 $52,000
Q1 2024 May 15, 2024	SELL	$4.9 - $6.91 $8,829 - $12,451	-1,802 Reduced 12.32%	12,825 $62,000
Q4 2023 Feb 14, 2024	BUY	$4.56 - $6.59 $16,849 - $24,350	3,695 Added 33.8%	14,627 $82,000
Q3 2023 Nov 14, 2023	SELL	$5.2 - $7.32 $23,311 - $32,815	-4,483 Reduced 29.08%	10,932 $67,000
Q2 2023 Aug 14, 2023	BUY	$4.11 - $6.81 $12,046 - $19,960	2,931 Added 23.48%	15,415 $98,000
Q1 2023 May 15, 2023	SELL	$4.0 - $4.67 $102,132 - $119,239	-25,533 Reduced 67.16%	12,484 $50,000
Q4 2022 Feb 14, 2023	BUY	$3.75 - $7.69 $2,640 - $5,413	704 Added 1.89%	38,017 $171,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.47 $149,362 - $196,180	20,716 Added 124.82%	37,313 $280,000

5.82M

15K

Ticker CSBR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,522,400
Market Cap $102M
Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.